Investor directory

Subhkam Ventures

Subhkam Ventures, established in 1999 by Rakesh S. Kathotia in Mumbai, India, operates as a family office specializing in private equity, venture capital, and public market investments. With over 20 years of experience in financial services and capital markets, Subhkam focuses on investment opportunities in midsized companies, offering growth capital and, in select cases, initial-stage funding. The firm aims to identify and capitalize on robust investment prospects that promise substantial medium to long-term capital appreciation. In addition to providing financial resources, Subhkam actively supports its investee companies in realizing their potential through strong partnerships. Its investment portfolio spans a diverse array of industries, including infrastructure, biotechnology, financial services, aerospace, telecom, real estate, tourism, waste management, and healthcare.
http://www.subhkam.com
https://crunchbase.com/organization/subhkam-ventures
https://linkedin.com/company/subhkam-capital-ltd
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=38447616
https://www.privateequityinternational.com/database/#/profile?id=12163

Rakesh S Kathotia

Founder

Rishabh R. Kathotia

Director

Yashasvi Kathotia

Director

Manu Punnoose

Managing Director

Past deals in Zambia

Bharat Biotech

Venture Round in 2019
Bharat Biotech Ltd. is a biotechnology company based in Hyderabad, India, specializing in the research, development, and manufacture of vaccines and biotherapeutics. Established in 1996, the company offers a diverse range of products, including vaccines such as Revac-B+, a recombinant hepatitis-B vaccine; TYPBAR, a typhoid vaccine; BIOPOLIO, a poliomyelitis vaccine; and INDIRAB, a rabies vaccine. Additionally, Bharat Biotech produces various biotherapeutics, like REGEN-D, a recombinant human epidermal growth factor gel for diabetic foot ulcers and burns, as well as treatments for osteoarthritis and other conditions. The company also provides women's healthcare products and has developed a cell culture H1N1 swine flu vaccine. Bharat Biotech exports its products to several countries, including Kenya, Zambia, and the Philippines, with a focus on creating affordable and effective therapies for neglected diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.